

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Cancelled)
2. (Currently amended) An isolated monocyte-derived multipotent cell (MOMC) expressing CD14, CD34, CD45 and type I collagen, wherein the cell ~~is capable of differentiating~~ differentiates into osteoblasts, skeletal myoblasts or chondrocytes, and the ~~monocyte-derived multipotent cell (MOMC)~~ is obtained by culturing peripheral blood mononuclear cells (PBMCs) in vitro on fibronectin, and collecting fibroblast-like cells expressing CD14 and CD34.
3. (Currently amended) The isolated monocyte-derived multipotent cell (MOMC) according to claim 2, that ~~is capable of differentiating~~ differentiates into mesenchymal cells by a culture under a condition inducing differentiation into mesenchymal tissues.
4. (Currently amended) The isolated monocyte-derived multipotent cell (MOMC) according to claim 3, wherein the mesenchymal cells are adipocytes.
5. (Currently amended) The isolated monocyte-derived multipotent cell (MOMC) according to claim 2, that ~~is capable of differentiating~~ differentiates into myocardial cells by a coculture with cultured myocardial cells.
6. (Currently amended) The isolated monocyte-derived multipotent cell (MOMC) according to claim 2, that ~~is capable of differentiating~~ differentiates into neurons by a coculture with cultured neurons.

7. (Currently amended) The isolated monocyte-derived multipotent cell (MOMC) according to claim 2, that ~~is capable of differentiating~~ differentiates into endothelial cells by a culture under a condition maintaining endothelial cells.
8. (Currently amended) The isolated monocyte-derived multipotent cell (MOMC) according to claim 2, that ~~is capable of differentiating~~ differentiates into mesodermal cells.
9. (Withdrawn) A method for preparing a monocyte-derived multipotent cell according to claim 2, comprising culturing peripheral blood mononuclear cells (PBMCs) in vitro on fibronectin, and collecting fibroblast-like cells expressing CD14 and CD34.
10. (Withdrawn) The method for preparing a monocyte-derived multipotent cell according to claim 9, comprising culturing in vitro on fibronectin for 5 to 14 days.
11. (Withdrawn) A mesenchymal progenitor, a mesenchymal cell or a mesenchymal tissue induced by culturing the monocyte-derived multipotent cell according to claim 2, under a condition inducing differentiation into mesenchymal tissues.
12. (Withdrawn) The mesenchymal progenitor, the mesenchymal cell or the mesenchymal tissue according to claim 11, wherein the mesenchymal cells are osteoblasts, skeletal myoblasts, chondrocytes or adipocyte.
13. (Withdrawn) A myocardial progenitor, a myocardial cell or a myocardial tissue induced by culturing the monocyte-derived multipotent cell according to claim 2, under a condition inducing differentiation into cardiac muscle such as a coculture with cultured myocardial cells.
14. (Withdrawn) A neural progenitor, a neuron or a nerve tissue induced by culturing the monocyte-derived multipotent cell according to claim 2, under a condition inducing differentiation into nerve, such as a coculture with cultured neuron.
15. (Withdrawn) An endothelial progenitor, an endothelial cell or an endothelial tissue induced by culturing the monocyte-derived multipotent cell according to claim 2, under a

condition inducing differentiation into endothelium, such as a culture under a condition maintaining endothelial cells.

16. (Withdrawn) A mesodermal progenitor, a mesodermal cell or a mesodermal tissue induced to differentiate from the monocyte-derived multipotent cell according to claim 2, under a condition inducing differentiation into mesodermal cell or mesodermal tissue, such as a culture under a condition maintaining mesodermal cells.
17. (Cancelled)
18. (Cancelled)
19. (Withdrawn) A treating method comprising administering the monocyte-derived multipotent cell according to claim 2 and/or mesodermal progenitors, mesodermal cells and/or mesodermal tissues induced to differentiate from the monocyte-derived multipotent cell.
20. (Withdrawn) A treating method comprising administering the monocyte-derived multipotent cell according to claim 2 and/or neural progenitors, neurons and/or nerve tissues induced to differentiate from the monocyte-derived multipotent cell.
21. (Cancelled)
22. (Withdrawn) A method for preparing the monocyte-derived multipotent cell according to claim 21, comprising culturing in vitro on fibronectin for 5 to 14 days.